Erasca shares sink after patient death in early-stage cancer drug trial

Erasca shares fell more than 35% premarket after the company disclosed a patient death in an early-stage trial of its experimental cancer drug. Analysts said the incident was unlikely to indicate a broader safety issue, but the announcement still pressured sentiment sharply. The move is material for the individual stock, though not likely to have broad sector implications.

Analysis

Erasca shares fell more than 35% premarket after the company disclosed a patient death in an early-stage trial of its experimental cancer drug. Analysts said the incident was unlikely to indicate a broader safety issue, but the announcement still pressured sentiment sharply. The move is material for the individual stock, though not likely to have broad sector implications.